Peer Exchange

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Clinical Significance of MRD Testing in MM
July 26, 2019 – 
Experts discuss clinical implications and the significance of minimal residual disease (MRD) testing in patients with multiple myeloma.
Osteoporosis and Fractures: Treatment Costs Versus Benefits
July 25, 2019 – 
Key opinion leaders discuss the direct and indirect costs of fractures in patients with osteoporosis and remark on the benefits of properly counseling patients about risks of fractures and goals of therapy.
Financial Costs and the Treatment of Osteoporosis
July 25, 2019 – 
Considerations for recommending a novel therapy to a patient with osteoporosis based on current costs, accessibility, and financial coverage.
Economic Burden and Challenges of Trial of SMA
July 22, 2019 – 
The panel shed a light on the economic burden of spinal muscular atrophy and the challenges of trial design.
Diagnostic Tests and Scales of SMA
July 22, 2019 – 
John Brandsema, MD, discusses the diagnostic process for spinal muscular atrophy, including the different functional motor scales used to measure patient function.
Practical Implications of the MAIA Study for MM
July 19, 2019 – 
Experts discuss the practical implications of the MAIA study for patients with newly diagnosed transplant-ineligible multiple myeloma.
Initiating Treatment in Relapsed-Refractory MM
July 19, 2019 – 
Discussion on the personal approaches toward treatment for patients with relapsed or refractory multiple myeloma.
What Is the Cost of Recurrence in Multiple Myeloma?
July 19, 2019 – 
Experts review the economic factors that play into the high costs of treatment and care for patients with multiple myeloma.
Osteoporosis: Selecting Between Novel Therapies
July 19, 2019 – 
Factors that affect a clinician’s willingness to recommend a novel treatment option for the management of osteoporosis.
Romosozumab in Clinical Trials for Osteoporosis
July 19, 2019 – 
Perspective regarding the rationale for treating patients with osteoporosis with romosozumab based on recent clinical trials.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.